This application constitutes a renewal on the part of the University of California Los Angeles (UCLA) for a Center for AIDS Research (CFAR) grant. This grant will fund activities and programs conducted by the UCLA CFAR within the UCLA AIDS Institute. The UCLA CFAR was set up in 1988, and the AIDS Institute was established in 1992 to coordinate all AIDS research, clinical and educational activities at the University and its affiliated teaching hospitals under one central administration. The overall organization of the AIDS Institute and the CFAR was restructured in 2005, in order to more efficiently and effectively manage the AIDS research activities with a bottom-up approach to governance, allowing participation by all faculty in all of our programs. This renewal application includes CFAR core services and activities that are designed to advance knowledge of HIV/AIDS through the basic, clinical, and behavioral sciences. The overall mission of the UCLA CFAR is to create synergies among diverse disciplines that result in significant breakthroughs in the understanding, prevention and treatment of HIV infection-with particular emphasis on high-value cross disciplinary collaborations. The UCLA CFAR consists of more than 200 investigators who are responsible for research projects that encompass virtually all aspects of HIV/AIDS biology, clinical studies, and behavioral science. UCLA has consistently been ranked among the top institutions for excellence in AIDS research, education and teaching, and clinical programs. The role of the CFAR is to foster collaboration and build linkages both within and outside the university, through support of scientific and administrative core facilities, and the provision of seed grant funding for highly meritorious collaborative and interdisciplinary research projects. The action plan for the first year of requested support is summarized as follows: The CFAR plans to continue supporting nine of the cores funded by the previous CFAR grant: Administrative Core, Developmental Core, Virology/BSL3 Tissue Culture Core, Cytometry Core, Humanized Mouse Core, Gene and Cellular Therapy Core, Mucosal Immunology Core, a Clinical Research Facilitation Core and the Biostatistics Core. Based upon changing epidemiology, needs assessments, strategic planning and revised short-and long-term goals, one core was eliminated and we developed an HIV+ and HIV- subject registry through our Clinical Research Facilitation Core. Inclusion of this resource will be highly beneficial to clinical, behavioral and basic science studies.

Public Health Relevance

Research into the pathogenesis, treatment and social aspects of HIV disease is needed to end this epidemic. Our program is designed to integrate clinical, behavioral and basic sciences and to provide valuable core services to facilitate AIDS research. Metropolitan Los Angeles is a major epicenter for the AIDS epidemic and one of the most culturally diverse regions in the nation, and our programs are designed to reach out to these diverse communities. We are particularly proud that 50% of the patients recruited into our clinical trials in recent years are members of minority communities particularly hard hit by this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI028697-28S1
Application #
9646982
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Namkung, Ann S
Project Start
1997-07-01
Project End
2019-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
28
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Woo, Jin Seok; Srikanth, Sonal; Kim, Kyun-Do et al. (2018) CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses. J Immunol 201:1174-1185
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Arfer, Kodi B; Tomlinson, Mark; Mayekiso, Andile et al. (2018) Criterion validity of self-reports of alcohol, cannabis, and methamphetamine use among young men in Cape Town, South Africa. Int J Ment Health Addict 16:45-52
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Shannon, Chelsea Lee; Bristow, Claire; Hoff, Nicole et al. (2018) Acceptability and Feasibility of Rapid Chlamydial, Gonococcal, and Trichomonal Screening and Treatment in Pregnant Women in 6 Low- to Middle-Income Countries. Sex Transm Dis 45:673-676
Furler, Robert L; Nixon, Douglas F; Brantner, Christine A et al. (2018) TGF-? Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction. Cancers (Basel) 10:
Sato, Kei; Misawa, Naoko; Takeuchi, Junko S et al. (2018) Experimental Adaptive Evolution of Simian Immunodeficiency Virus SIVcpz to Pandemic Human Immunodeficiency Virus Type 1 by Using a Humanized Mouse Model. J Virol 92:
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Heard, Jeffrey J; Phung, Ivy; Potes, Mark I et al. (2018) An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer 18:69
Young, Sean D; Mercer, Neil; Weiss, Robert E et al. (2018) Using social media as a tool to predict syphilis. Prev Med 109:58-61

Showing the most recent 10 out of 942 publications